Live-attenuated tetravalent dengue vaccines: The needs and challenges of post-licensure evaluation of vaccine safety and effectiveness (scientific article published on 8 September 2017)

Substitution of wild-type yellow fever Asibi sequences for 17D vaccine sequences in ChimeriVax-dengue 4 does not enhance infection of Aedes aegypti mosquitoes

Q27487448

A prospective study of dengue infections in Bangkok

Q28296365

Dengue disease surveillance: an updated systematic literature review.

Q30209910

A prospective seroepidemiologic study on dengue in children four to nine years of age in Yogyakarta, Indonesia I. studies in 1995-1996.

Q30778819

Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial

Q34428943

Efficacy of a tetravalent dengue vaccine in children in Latin America.

Q34446032

Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease

Q34487028

Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year

Q34952330

Preexisting neutralizing antibody responses distinguish clinically inapparent and apparent dengue virus infections in a Sri Lankan pediatric cohort

Q35221318

Symptomatic Dengue in Children in 10 Asian and Latin American Countries

Q35967652

The Long-Term Safety, Public Health Impact, and Cost-Effectiveness of Routine Vaccination with a Recombinant, Live-Attenuated Dengue Vaccine (Dengvaxia): A Model Comparison Study

Q36206692

Rotavirus vaccine effectiveness in low-income settings: An evaluation of the test-negative design

Q37499028

Long-term safety assessment of live attenuated tetravalent dengue vaccines: deliberations from a WHO technical consultation

Q37706823

Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms

Q37901360

Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection

Q38087545

Preparing for dengue vaccine introduction in ASEAN countries: recommendations from the first ADVA regional workshop

Q38202176

The relevance of dengue virus genotypes surveillance at country level before vaccine approval

Q38284671

The test-negative design for estimating influenza vaccine effectiveness

Q38427246

Points for Consideration for dengue vaccine introduction - recommendations by the Dengue Vaccine Initiative

Q38664198

Dissecting Antibodies Induced by a Chimeric Yellow Fever-Dengue, Live-Attenuated, Tetravalent Dengue Vaccine (CYD-TDV) in Naive and Dengue-Exposed Individuals.

Q38727029

Enhanced severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks

Q39038287

Theoretical Basis of the Test-Negative Study Design for Assessment of Influenza Vaccine Effectiveness

Q39429254

Critique of World Health Organization Recommendation of a Dengue Vaccine

Q40093858

A comparative study on active and passive epidemiological surveillance for dengue in five countries of Latin America

Q40119834

Risk factors in dengue shock syndrome.

Q40651443

P407

language of work or name

English

Q1860

P921

main subject

attenuated vaccine

Q1810913

vaccine safety

Q105256838

P577

publication date

2017-09-08

P1433

published in

Vaccine

Q7907941

P1476

title

Live-attenuated tetravalent dengue vaccines: The needs and challenges of post-licensure evaluation of vaccine safety and effectiveness

Reverse relations

cites work (P2860)

Q47143756	A universal mammalian vaccine cell line substrate
Q92093930	Cell-mediated immune responses to different formulations of a live-attenuated tetravalent dengue vaccine candidate in subjects living in dengue endemic and non-endemic regions
Q51336222	Chikungunya, Dengue, and Zika in Immunocompromised Hosts
Q52662743	Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines
Q91341741	Deliberations of the Strategic Advisory Group of Experts on Immunization on the use of CYD-TDV dengue vaccine
Q91977532	Economic Evaluations of Dengue Vaccination in the Southeast Asia Region: Evidence From a Systematic Review
Q43046550	Encouraging results but questions remain for dengue vaccine
Q58595152	Epitope resurfacing on dengue virus-like particle vaccine preparation to induce broad neutralizing antibody
Q97565389	Ethics of a partially effective dengue vaccine: Lessons from the Philippines
Q92843954	Feasibility of case-control and test-negative designs to evaluate dengue vaccine effectiveness in Malaysia
Q61798573	Heterogeneities in dengue spatial-temporal transmission in Brazilian cities and its influence on the optimal age of vaccination
Q90353798	Isolation and molecular characterization of dengue virus clinical isolates from pediatric patients in New Delhi
Q90354678	Predictors of Major Bleeding and Mortality in Dengue Infection: A Retrospective Observational Study in a Tertiary Care Centre in South India
Q90713910	Production of tetravalent dengue virus envelope protein domain III based antigens in lettuce chloroplasts and immunologic analysis for future oral vaccine development
Q64375183	T Lymphocytes as Measurable Targets of Protection and Vaccination Against Viral Disorders
Q63246530	The Conserved Molecular Determinants of Virulence in Dengue Virus
Q59360735	The dynamic role of dengue cross-reactive immunity: changing the approach to defining vaccine safety and efficacy

P356	DOI	10.1016/J.VACCINE.2017.08.066
P698	PubMed publication ID	28893477